Home/Pipeline/ALN-BCAT

ALN-BCAT

Hepatocellular Carcinoma

Phase 1Active

Key Facts

Indication

Hepatocellular Carcinoma

Phase

Phase 1

Status

Active

Company

Alnylam Pharmaceuticals

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals' mission is to harness RNA interference (RNAi) to develop transformative medicines for patients with serious diseases. The company has achieved its goal of building a sustainable, top-tier biopharmaceutical company, with five FDA-approved products generating significant revenue and a deep clinical pipeline. Its strategy, 'Alnylam 2030,' focuses on expanding into prevalent diseases, advancing next-generation platforms, and scaling global commercial and manufacturing operations to serve millions of patients.

View full company profile

Therapeutic Areas

Rare Genetic Diseases Cardio-Metabolic Diseases Hepatic Infectious Diseases Central Nervous System (CNS) Diseases Ocular Diseases

Other Hepatocellular Carcinoma Drugs

Drug	Company	Phase	Status
Namodenoson (CF102)	Can Fite Biopharma	Phase IIb/III	Active
DCR-MYC	Dicerna Pharmaceuticals	Preclinical	Discontinued
RYZ801	RayzeBio	Preclinical	Active
RG6139 (RO7247669)	Chugai Pharmaceutical	Phase III	Active
HCC Program	Arcellx	Discovery	Active
TTFields	Novocure	Pilot	Active
RP2	Replimune	Phase 2	Active, Enrolling
188RNL-BAM	Plus Therapeutics	Preclinical	In Development
Temferon	Genenta Science	Preclinical	Investigational